In patent litigation between branded and generic manufacturers of canine flea & tick products, CRA was asked to assess irreparable harm. CRA examined effects from the entry and ongoing sales of the generic products, business losses suffered by the branded manufacturer and whether they could be attributed to the sale of the generic products, the influence of new channels, such as the internet, and the impact of newer, more effective classes of parasiticides. CRA submitted a declaration on irreparable harm.
IP Literature Watch: March 2024
In this month’s IP Literature Watch we include an article analyzing four case studies of controversy over license design in open-source software and hardware...